[1]Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023[J]. J Am Coll Cardiol,2025 ,86(22):2167-2243.
[2]Sun J H, Qiao Y N, Zhao M, et al. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15-39 years in 204 countries/territories, 1990-2019: a systematic analysis of Global Burden of Disease Study 2019[J]. BMC Med, 2023, 21(1): 222.
[3]中国心血管病预防指南(2017)写作组, 中华心血管病杂志编辑委员会. 中国心血管病预防指南(2017)[J]. 中华心血管病杂志, 2018, 46(1): 10-25.
[4]Reese J A, Roman M J, Deen J F, et al. Subclinical atherosclerosis in adolescents and young adults and the risk of cardiovascular disease: the Strong Heart Family Study (SHFS)[J]. Nutr Metab Cardiovasc Dis, 2022, 32(8): 1863-1871.
[5]中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南基层版[J]. 中华心血管病杂志, 2023, 51(4): 343-363.
[6]Bushnell C, Kernan W N, Sharrief A Z, et al. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association[J]. Stroke, 2024, 55(12): e344-e424.
[7]National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification[M]. London: National Institute for Health and Care Excellence, 2023.
[8]American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S144-S174.
[9]中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会,中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南[J]. 中华心血管病杂志, 2020, 48(12): 1000-1038.
[10]Yang X L, Li J X, Hu D S, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (prediction for ASCVD risk in China)[J]. Circulation, 2016, 134(19): 1430-1440.
[11]Yang X L, Chen J C, Li J X, et al. Risk stratification of atherosclerotic cardiovascular disease in Chinese adults[J]. Chronic Dis Transl Med, 2016, 2(2): 102-109.
[12]Liu J, Hong Y L, D'Agostino R B Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study[J]. JAMA, 2004, 291(21): 2591-2599.
[13]Wu Y F, Liu X Q, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation, 2006, 114(21): 2217-2225.
[14]中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10): 766-783.
[15]中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非ST段抬高型急性冠脉综合征诊断和治疗指南(2024)[J]. 中华心血管病杂志, 2024, 52(6): 615-646.
[16]中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3): 235-275.
[17]中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618.
[18]中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国脑出血诊治指南(2019)[J]. 中华神经科杂志, 2019, 52(12): 994-1005.
[19]中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组, 中华医学会神经病学分会神经血管介入协作组. 中国蛛网膜下腔出血诊治指南2019[J]. 中华神经科杂志, 2019, 52(12): 1006-1021.
[20]中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志, 2024, 57(6): 523-559.
[21]Rubin D B. Multiple imputation after 18+ years[J]. J Am Stat Assoc, 1996, 91(434): 473-489.
[22]国家“十五”攻关冠心病、脑卒中综合危险度评估及干预. 国人缺血性心血管病发病危险的评估方法及简易评估工具的开发研究[J]. 中华心血管病杂志, 2003, 31(12): 893-901.
[23]D'Agostino R B Sr, Vasan R S, Pencina M J, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study[J]. Circulation, 2008, 117(6): 743-753.
[24]SCORE2 Working Group and Esc Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe[J]. Eur Heart J, 2021, 42(25): 2439-2454.
[25]Zhou L, Chen Y Y, Sun N L, et al. Family history of hypertension and arterial elasticity characteristics in healthy young people[J]. Hypertens Res, 2008, 31(5): 833-839.
[26]Kappelle P J W H, Gansevoort R T, Hillege J L, et al. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein[J]. J Intern Med, 2011, 269(2): 232-242.
[27]Nomikos T, Panagiotakos D, Georgousopoulou E, et al. Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study[J]. Lipids Health Dis, 2015, 14: 108.
[28]Wan E Y F, Fong D Y T, Fung C S C, et al. Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: a population-based retrospective cohort study[J]. Diabetes Obes Metab, 2018, 20(2): 309-318.
[29]Zhou Z, Ong K L, Whelton S P, et al. Impact of blood lipids on 10-year cardiovascular risk in individuals without dyslipidemia and with low risk factor burden[J]. Mayo Clin Proc, 2022, 97(10): 1883-1893.
[30]Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study[J]. Metabolism, 2008, 57(3): 387-392.
[31]Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data[J]. Hepatology, 2010, 52(3): 1156-1161.
[32]Paolicchi A, Emdin M, Ghliozeni E, et al. Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity[J]. Circulation, 2004, 109(11): 1440.
|